About Vantage

Written by a team of award-winning journalists, Vantage, previously known as EP Vantage, provides daily financial analysis of key industry catalysts including: regulatory and patent decisions, marketing approvals, licensing deals, and M&A – giving fresh angles and insight to both current and future industry triggers.

Launched in 2007 by Evaluate, Vantage’s unique access to Evaluate data allows unrivalled, forward-looking coverage of the pharmaceutical, biotech and medtech industries, allowing us to cover potential market catalysts weeks and even months ahead of other industry sources.

While access to Evaluate financial data helps to put events into context, quantifying impacts on product or company valuation.

Although part of Evaluate, Vantage is a distinct and editorially independent entity.

What our readers say about Vantage

Vantage is one of my must reads... It's a valuable resource for us.

Anthony M, Novartis

I gain a deeper understanding of the complex mesh of issues we in the pharma industry are facing as we progress through this time of business model review.

Strategy Director, Global Pharma

It is always one of my first reads, and towers above most of the other contributors I encounter, particularly when writing about complex subjects.

Manager, Global Pharma

I know for a fact that every single person on the life sciences team subscribes and reads Vantage once a day.

Vishwas S, Bank of America

Find Us

Find Us


11-29 Fashion Street,

London E1 6PX

United Kingdom

  • +44 (0)20 7539 1819

Follow us: